# Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

> **NCT03750669** · PHASE3 · COMPLETED · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 324 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Resectable
- Neoadjuvant Chemotherapy

## Interventions

- **DRUG:** AG regimen
- **DRUG:** mFolfirinox

## Key facts

- **NCT ID:** NCT03750669
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-20
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03750669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03750669, "Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03750669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*